Sysmex Corporation
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 16 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Top Mutual Funds / ETFs
Updated 2026/01/11Major Holders
Updated 2026/01/11| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT.
|
10.4M | -4.15% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
6.6M | +0.03% | |
|
BNY Mellon Strategic Funds, Inc.-BNY Mellon International Stock Fund
|
5.5M | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
4.2M | +2.84% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
3.4M | +1.21% | |
|
-Price (T.Rowe) International Core Equity Trust
|
2.5M | +3.15% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
4.2K | -4.06% |
Dividend History 4Years Growth
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥36 | +24.1% |
| 2024 | ¥29 | +3.6% |
| 2023 | ¥28 | +6.3% |
| 2022 | ¥26 | +8.2% |
| 2021 | ¥24 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥363,780M | ¥410,502M | ¥461,510M | ¥508,643M |
| Gross Profit | ¥190,585M | ¥216,082M | ¥242,497M | ¥271,977M |
| Operating Income | ¥67,418M | ¥76,049M | ¥80,595M | ¥90,796M |
| Pretax Income | ¥65,255M | ¥70,279M | ¥76,986M | ¥82,739M |
| Net Income | ¥44,092M | ¥45,784M | ¥49,639M | ¥53,669M |
| EPS | ¥70.16 | ¥72.91 | ¥79.24 | - |
| Operating Margin | 18.53% | 18.53% | 17.46% | 17.85% |
| Balance Sheet | ||||
| Total Assets | ¥483,707M | ¥531,074M | ¥618,920M | ¥665,268M |
| Total Equity | ¥348,303M | ¥387,665M | ¥432,045M | ¥463,776M |
| Total Liabilities | ¥135,404M | ¥143,409M | ¥186,875M | ¥201,492M |
| Cash | ¥73,752M | ¥69,460M | ¥75,507M | ¥89,570M |
| Interest-bearing Debt | ¥22,279M | ¥22,591M | ¥55,339M | ¥64,735M |
| Equity Ratio | 72.01% | 73.00% | 69.81% | 69.71% |
| D/E Ratio | 0.06 | 0.06 | 0.13 | 0.14 |
| Cash Flow | ||||
| Operating CF | ¥58,739M | ¥68,835M | ¥63,905M | ¥88,246M |
| Investing CF | -¥35,052M | -¥51,751M | -¥54,970M | -¥52,488M |
| Financing CF | -¥20,542M | -¥24,234M | -¥9,013M | -¥24,322M |
| Free CF | ¥26,705M | ¥26,330M | ¥13,714M | ¥38,287M |
| Efficiency | ||||
| ROE | 12.66% | 11.81% | 11.49% | 11.57% |
| ROA | 9.12% | 8.62% | 8.02% | 8.07% |
Latest IR Information
-
No IR information found for this company.
Searched stock code: 6869
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥2,344
Rating Score: - (Based on 16 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte counts; coagulation, blood gas/ electrolyte/ urinalysis, cells/ microorganisms, including particle counter/analyzer CDA-1000/1000B, an equipment which is capable of counting cells, yeast, algae, bacteria, and others. The company serves national and other public hospitals, general hospitals, universities, research institutes, other medical institutions, etc. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
